Immunic AG – Home

Immunic AG is a specialist in selective oral drugs in immunology and focused on developing novel oral therapies with best-in-class potential for chronic inflammatory and autoimmune diseases.

Immunic is based in the Munich biotech hub Martinsried, Germany, and has subsidiaries in Halle/Saale, Germany, and Melbourne, Australia. The company currently develops three products for the treatment of chronic inflammatory and autoimmune diseases including e.g. inflammatory bowel disease, multiple sclerosis and psoriasis. Immunic’s lead development program, IMU-838, is currently in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with additional phase 2 trials in Crohn’s disease and primary sclerosing cholangitis planned for 2019. IMU-935 is a best-in-class inverse agonist of the nuclear receptor RORγt and currently in preclinical development. IMU-856 is a newly developed and orally available small molecule aiming at a yet undisclosed target and currently in preclinical testing.

Immunic Therapeutics to Participate in Investor and Medical Conferences in March

Planegg-Martinsried, Germany, February 28, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology company, today announced that management will participate in the following conferences in March: To schedule a ...
Read More

Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis

Planegg-Martinsried, Germany, February 26, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology company, today announced enrollment of the first patient in a phase 2 clinical study of IMU-838 ...
Read More

Immunic Therapeutics to Present at the BIO CEO & Investor Conference on February 11

Planegg-Martinsried, Germany, February 6, 2019 – Immunic AG (Immunic), a privately-held clinical-stage biotechnology company, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will present at the BIO CEO & ...
Read More